Evidence map›Paper›PMID 39252870›Full record

ArticleOpen forum infectious diseases2024

Impact of the Coronavirus Disease 2019 Pandemic on Substance Use Disorder Risk Among People Living With Human Immunodeficiency Virus (HIV) Enrolled in HIV Care in the United States: An Interrupted Time Series Analysis.

Jennifer P Jain, Megan J Heise, Nadra E Lisha, Carlos H Moreira, David V Glidden, Greer A Burkholder, Heidi M Crane, Jeffrey M Jacobson, Edward R Cachay, Kenneth H Mayer and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jennifer P JainDivision of Prevention Science, University of California, San Francisco, California, USA.
Megan J HeiseDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-6651-2381
Nadra E LishaDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Carlos H MoreiraDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-5888-1419
Greer A BurkholderDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Heidi M CraneDivision of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Jeffrey M JacobsonDivsion of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, USA.
Edward R CachayDivision of Infectious Diseases, University of California, San Diego, California, USA.
Kenneth H MayerDepartment of Medicine, Harvard University, Boston, Massachusetts, USA.
Sonia NapravnikDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-9032-3713
Richard D MooreDivision of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
Carol Dawson-RoseSchool of Nursing, University of California, San Francisco, California, USA.
Mallory O JohnsonDivision of Prevention Science, University of California, San Francisco, California, USA.
Katerina A ChristopoulosDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
Monica GandhiDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-7025-1994
Matthew A SpinelliDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-6368-8664

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
Women, Intersectionality, Substance Use and HIV ( WISH)K01DA056306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Payaal Jain · 2022 to 2026
$1.0M
Mentoring Patient-Oriented Research on Advances to Optimize Engagement in HIV CareK24AI167805 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katerina A Christopoulos · 2022 to 2026
$963k
NIAID NIH HHS K24 AI167805NIAID NIH HHS R01 AI158013NIDA NIH HHS K01 DA056306NIDA NIH HHS L60 DA054664NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

Background: Rising overdose deaths globally and increased social isolation during the coronavirus disease 2019 (COVID-19) pandemic may have disproportionately impacted people with human immunodeficiency virus (PWH) with substance use disorders (SUD). We examined trends in SUD risk among PWH before and after the COVID-19 shelter-in-place (SIP) mandate. Methods: Data were collected between 2018 and 2022 among PWH enrolled across 8 US sites in the Centers for AIDS Research Network of Integrated Clinical Systems cohort. We evaluated changes in moderate/high SUD risk after SIP using interrupted time series analyses. Results: There were 7126 participants, including 21 741 SUD assessments. The median age was 51 (interquartile range, 39-58) years; 12% identified as Hispanic or Latino/Latina, 46% Black/African American, and 46% White. Moderate/high SUD risk increased continuously after the pandemic's onset, with 43% (95% confidence interval [CI], 40%-46%) endorsing moderate/high SUD risk post-SIP, compared to 24% (95% CI, 22%-26%) pre-SIP ( Conclusions: The rising prevalence of SUD through late 2022 could be related to an increase in isolation and reduced access to substance use and HIV treatment caused by disruptions due to COVID-19. A renewed investment in integrated substance use treatment is vital to address the combined epidemics of substance use and HIV following the COVID-19 pandemic and to support resilience in the face of future disruptions.

Indexed as

COVID-19depression symptomsHIV/AIDSLGBTQsubstance use disorder

Identifiers

PMID39252870
PMCPMC11382144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.